(Q27851722)

English

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum (English)

1 reference

13 November 2016

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

D H Yoon

1

0 references

M-H Ryu

2

0 references

Y S Park

3

0 references

H J Lee

4

0 references

C Lee

5

0 references

B-Y Ryoo

6

0 references

J-L Lee

7

0 references

H-M Chang

8

0 references

T W Kim

9

0 references

Y-K Kang

10

0 references

language of work or name

0 references

publication date

13 March 2012

0 references

British Journal of Cancer

1 reference

106

0 references

1039-44

0 references

6

0 references

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

20 March 2017

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

7 April 2017

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

7 April 2017

The TOR pathway: a target for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

7 April 2017

The mTOR pathway: a new target in cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Mechanism and management of AKT inhibitor-induced hyperglycemia

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

The prevalence of PIK3CA mutations in gastric and colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22343617

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22343617

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.47

0 references

Dimensions Publication ID

0 references

1 reference

13 November 2016

1 reference

13 November 2016

ResearchGate publication ID

0 references

Springer Nature article ID

10.1038/bjc.2012.47

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851722&oldid=1951401599"